Our History
Alector is rooted in an inspiration to make new connections and the conviction to challenge accepted norms. Learn more about how we got here.
2024
Dosed first participant in PROGRESS-AD, the global Phase 2 clinical trial of AL101/GSK4527226 in patients with early Alzheimer’s disease
Granted Breakthrough Therapy Designation for latozinemab in FTD-GRN
Achieved target enrollment with 103 symptomatic and 16 at-risk FTD-GRN participants in the pivotal, randomized, double-blind, placebo-controlled INFRONT-3 Phase 3 clinical trial of latozinemab
Completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial of AL002 in early Alzheimer’s disease
Received FDA clearance of an IND application for AL101 in the treatment of early Alzheimer’s disease
2023
2022
Presented 12-month results from AL001 (latozinemab) Phase 2 clinical study in symptomatic FTD-C9orf72 participants at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders
Presented 12-month results from AL001 Phase 2 clinical study in symptomatic FTD-GRN participants at Alzheimer’s Association International Congress
Presented data on AL002 program in Alzheimer’s disease at AAIC 2021
Forged collaborative agreement with GlaxoSmithKline to co-develop and co-commercialize progranulin franchise programs AL001 and AL101
Initiated INVOKE Phase 2 clinical trial of AL002 for treatment of patients with early Alzheimer’s disease
2021
2020
Commenced enrollment of AL001 INFRONT randomized Phase 3 clinical trial for treatment of patients with dementia with a progranulin gene mutation (FTD-GRN)
Shared initial data from Phase 1b and Phase 2 clinical studies of AL001 at Alzheimer’s Association International Congress
Published preclinical data for AL002 in the Journal of Experimental Medicines
Presented preclinical data from immuno-oncology product candidates AL008 being developed for treatment of cancers
Initiated Phase 1 clinical trial of AL101 to increase progranulin levels in healthy volunteers
Granted Fast Track Designation for AL001 in frontotemporal dementia
Began INFRONT Phase 2 trial of AL001 for treatment of patients with frontotemporal dementia
Hired 100th employee
Announced data from INFRONT Phase 1b clinical trial of AL001 showing increases in progranulin levels to normal levels
Alector announces pricing of its initial public offering and starts trading on the Nasdaq
2019
2018
Began dosing in INVOKE Phase 1 trial of AL002 in healthy volunteers and participants with Alzheimer’s disease
Initiated Phase 1 clinical study of AL001 in healthy volunteers and participants with frontotemporal dementia that carry the GRN mutation
Received Orphan Drug designation from U.S. Food and Drug Administration for AL001 for the treatment of frontotemporal dementia
Closed $133M Series E crossover round financing with new and existing investors to advance immuno-neurology pipeline candidates into the clinic
Announced indications for first two therapeutic candidates: AL001 for frontotemporal dementia and AL002 for Alzheimer’s disease
Formed partnership with AbbVie to co-develop Alector’s Alzheimer’s-focused lead program AL002
2017
2016
Added new investors through $29.5M Series D financing
Dementia Discovery Fund, an innovative global investment fund launched in October 2015, chooses Alector for first award
Raised $32M in Series C fund with investment from MRL Ventures, OrbiMed, Polaris, Google Ventures, Topspin Partners, and Mission Bay Capital, among others
Named one of 2015’s “Fierce 15” private companies by FierceBiotech
Disclosed research focus on immuno-neurology and discovery of 12 leads for new neurodegeneration treatments
2015
2014
Series B funding round closes with investments from Orbimed and Polaris Ventures
Disclosed generation of four novel antibody drugs against disease-altering targets and plan to read and took two forward in preclinical development
Signed collaborative research agreement with Johnson & Johnson Innovation Center to fund one target through proof-of-concept in disease models
Alector and Adimab announce strategic alliance to access antibody technologies
Co-founders Arnon Rosenthal, Ph.D., Tillman Gerngross and Errik Anderson launch Alector with announcement of Series A financing from Orbimed and Polaris Ventures
Alector moves to life science incubator QB3
Alector is incorporated
Selected Alector as the company name to represent heroic ideals ubiquitous in Greek mythology